The Effects of MediDrink Platinum+ and Fava Bean Protein Hydrolysate on Fitness in an Aged Population
Prospective, Open-Label, Multicenter Study to Characterise the Effects of Co-administration of MediDrink Platinum+ Formula Containing Novel Protein Blend SPR-01 and Fava Bean Protein Hydrolysate on Fitness in an Aged Population
Nuritas Ltd
75 participants
Sep 10, 2025
INTERVENTIONAL
Conditions
Summary
Examining the effects of MediDrink Platinum+ containing novel protein blend SRP-01 alone or when combined with PeptiStrong on clinical responses in elderly adults with sarcopenia
Eligibility
Inclusion Criteria8
- years or older
- BMI ≤ 25 kg/m²
- Malnourished (mini nutritional assessment MNA <11
- Sarcopenic: SARC-F score ≥ 4
- Capable or oral feeding either alone or assisted
- Ambulatory (WHO PS/ECOG 0-3)
- Ability to complete questionnaires and self assess health status
- Ability to provide consent
Exclusion Criteria11
- Patient cannot eat orally
- Acute Infection
- Proven Intestinal obstruction
- Co-morbidities requiring a special diet (diabetes, kidney disease etc.)
- Liver dysfunction
- Acute or chronic renal failure
- Uncontrollable nausea or vomiting
- Use of megestrol acetate or metabolic steroids
- Dietary supplement use in the last 3 months
- Known intolerance or allergy to the investigational products
- Participation in any clinical trial within the last 3 months
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
MediDrink Platinum+ containing novel protein blend SPR-01
MediDrink Platinum+ containing novel protein blend SPR-01 and PeptiStrong, fava bean protein hydrolysate
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07322653